The global varicella zoster HHV-3 infections market comprises of drugs used for the treatment of chickenpox and shingles caused by the Vericella-zoster virus. Chickenpox, also known as varicella, is a highly contagious disease caused by primary infection with varicella zoster virus. It causes a blistering rash and itching and affects people of all ages. However, it is more common among young children. Shingles, also known as herpes zoster, is a painful skin rash caused by reactivation of the varicella-zoster virus latent in nerve tissue.
The Global Varicella Zoster (HHV-3) Infections Market is estimated to be valued at USD 1.79 billion in 2024 and is expected to reach USD 2.52 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.3% from 2024 to 2031.
Key players operating in the varicella zoster HHV-3 infections market are Cangene Corporation, Novartis, GC Biopharma Corp, Pascoe Pharmazeutische Praeparate GmbH, SK Chemical Co. Ltd.
The key players are mainly focusing on developing advanced drugs to treat varicella zoster HHV-3 infections.
The increasing prevalence of Varicella Zoster HHV-3 Infections Market is the primary factor driving the growth of the market. As per the estimates of World Health Organization (WHO), around 130-150 million cases of chickenpox occur each year worldwide. Moreover, nearly 1 in 3 people in the United States gets shingles during their lifetime. Growing aging population is another factor fueling the market growth, as people aged 60 years or older are at higher risk of developing Herpes zoster virus infections.
Advancements in vaccines and drugs development are accelerating the growth of varicella zoster HHV-3 infections market. Leading biopharmaceutical companies are continuously investing in R&D to develop more effective vaccines and drugs. For instance, Shingrix, a non-live recombinant zoster vaccine by GlaxoSmithKline received FDA approval in 2017, which helped prevent HZ and PHN in older adults more effectively than Zostavax.
Market Trends
Increasing demand for combination therapies: The increasing demand for combination therapies with higher efficacy for treating varicella zoster infections is a major trend witnessed in the market. Several clinical trials are currently underway to evaluate the efficacy and safety of combination antiviral drugs.
Growing pipeline of injectable drugs: Major pharmaceutical manufacturers are focusing on developing long-acting injectable formulations to improve patient compliance and treatment outcomes for varicella zoster infections. For instance, GSK is developing a longer-acting vaccine to prevent shingles recurrence by modifying ADJUVANT SYSTEM 03 formulation.
Market Opportunities
Untapped emerging markets: Most emerging markets in Asia Pacific and Latin America regions have low availability and adoption of vaccines and drugs for varicella zoster HHV-3 infections treatment, representing major opportunities for players.
Increased government support: Favorable government initiatives and funding to prevent and control varicella zoster HHV-3 infections through vaccination programs present lucrative scope for the market players in terms of revenue generation.
Impact of COVID-19 on Varicella Zoster HHV-3 Infections Market Growth
The COVID-19 pandemic has significantly impacted the varicella zoster HHV-3 infections market. During the initial months of the pandemic, factors like lockdowns and fear of contracting infection led to postponement of non-essential medical treatments and screening programs. This led to a short-term decline in diagnosis and treatment of varicella zoster infections. However, as the pandemic progressed, the impact was not as drastic as initially anticipated. With development of better protocols for infection control and management of non-COVID patients, treatment and screening activities resumed gradually. Telemedicine also played a supportive role in continuing care for chronic patients. On the flip side, factors like increased stress levels during the pandemic might have aggravated outbreaks of infections like herpes zoster in susceptible population groups. Overall, while the short-term impact was negative, in the long run the market is expected to regain lost growth momentum. Investment in R&D for new drugs and vaccines will continue to drive future market prospects.
Varicella Zoster HHV-3 Infections Market in Europe
In terms of value, Europe accounted for a major share of the global varicella zoster HHV-3 infections market. Countries like Germany, United Kingdom, France, Italy, and Spain have continued to report a sizeable patient pool diagnosed with varicella zoster infections annually. This can be attributed to factors like the growing geriatric population who are at higher risk of reactivation of virus, and relatively higher awareness levels regarding early diagnosis and treatment. Initiatives by governments to include varicella vaccination in national immunization programs have also supported regional market growth over the years. Furthermore, strong presence of leading pharmaceutical companies involved in development and commercialization of antiviral drugs makes Europe an important varicella zoster market globally.
Fastest Growing Region in Varicella Zoster HHV-3 Infections Market
The Asia Pacific region is expected to witness the fastest growth in the varicella zoster HHV-3 infections market during the forecast period. This can be credited to elements like rising healthcare expenditure, expanding patient pool due to changing demographics, and greater focus of market players on countries like China, India, Indonesia, and Vietnam. Developing nations in the region are slowly including varicella vaccines in their routine immunization programs as per WHO guidelines. Increasing access to diagnosis and treatment options will also aid regional market prospects. Rising economic capabilities are encouraging local pharmaceutical firms to enter into vaccine production and distribution alliances. All these factors are anticipated to fuel Asia Pacific's growth trajectory in the varicella zoster infections market space.
Get more insights on — Varicella Zoster HHV-3 Infections Market
Get this Report in Japanese Language: 水痘・帯状疱疹 HHV-3 感染症市場
Get this Report in Korean Language: 수두 대상포진 HHV-3 감염 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)
